Quick Answer
C4 Therapeutics, Inc. reported Total Revenue of $35.95 million for fiscal year 2025.
C4 Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $35.95M +1.0% |
$35.58M +71.4% |
$20.76M -33.3% |
$31.10M -32.1% |
$45.78M | — |
| Revenue (ASC 606) | $35.95M +1.0% |
$35.58M +71.4% |
$20.76M -33.3% |
$31.10M -32.1% |
$45.78M | — |
| Net Income | -$104.99M +0.3% |
-$105.32M +20.5% |
-$132.49M -3.4% |
-$128.18M -52.8% |
-$83.89M -26.5% |
-$66.33M -94.5% |
| Diluted EPS | -$1.27 +16.4% |
-$1.52 +43.1% |
-$2.67 -1.9% |
-$2.62 -44.0% |
-$1.82 | — |
| Total Assets | $359.07M +2.7% |
$349.60M -7.1% |
$376.45M -12.6% |
$430.84M -15.0% |
$506.76M +26.6% |
$400.14M +238.4% |
| Cash and Equivalents | $74.60M +34.4% |
$55.50M -56.2% |
$126.59M +325.5% |
$29.75M -60.9% |
$76.12M -58.1% |
$181.73M +100.7% |
| Long-Term Debt | — | — | $0.00 -100.0% |
$9.20M -14.6% |
$10.77M +7.1% |
$10.05M |
| Stockholders Equity | $256.59M +18.8% |
$215.99M -12.2% |
$246.11M -14.9% |
$289.23M -25.8% |
$389.61M +38.8% |
$280.79M +350.8% |
| R&D Expense | $104.24M -5.8% |
$110.64M -6.0% |
$117.71M -0.1% |
$117.84M +24.5% |
$94.67M +20.7% |
$78.44M +63.2% |
| Operating Income | -$115.22M +3.7% |
-$119.61M +14.0% |
-$139.03M -7.3% |
-$129.53M -57.7% |
-$82.13M -35.9% |
-$60.45M -70.5% |
| Shares Outstanding | 96.91M +37.2% |
70.63M +16.8% |
60.47M +23.5% |
48.97M +0.6% |
48.69M +13.1% |
43.06M +2918.3% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $11.23M | -26.9% | +73.8% |
| Revenue (ASC 606) | September 30, 2025 | $11.23M | -26.9% | +73.8% |
| Net Income | September 30, 2025 | -$32.17M | -30.4% | -23.6% |
| Diluted EPS | September 30, 2025 | -$0.44 | -25.7% | -18.9% |
| Total Assets | September 30, 2025 | $265.49M | -29.4% | -10.5% |
| Cash and Equivalents | September 30, 2025 | $58.81M | -1.4% | -24.8% |
| Long-Term Debt | September 30, 2023 | $0.00 | -100.0% | — |
| Stockholders Equity | September 30, 2025 | $154.41M | -36.4% | -11.3% |
| R&D Expense | September 30, 2025 | $25.99M | -18.4% | -0.8% |
| Operating Income | September 30, 2025 | -$34.41M | -21.8% | -20.7% |
| Shares Outstanding | September 30, 2025 | 74.17M | +5.1% | +4.5% |
- C4 Therapeutics, Inc. reported Total Revenue of $35.95 million for fiscal year 2025.
- C4 Therapeutics, Inc. showed an increase of +1.0% in Total Revenue compared to the prior fiscal year.
- C4 Therapeutics, Inc. reported Revenue (ASC 606) of $35.95 million for fiscal year 2025.
- C4 Therapeutics, Inc. showed an increase of +1.0% in Revenue (ASC 606) compared to the prior fiscal year.
- C4 Therapeutics, Inc. reported Net Income of -$104.99 million for fiscal year 2025.
- C4 Therapeutics, Inc. showed an increase of +0.3% in Net Income compared to the prior fiscal year.
- C4 Therapeutics, Inc. reported Diluted EPS of $1.27 per share (loss) for fiscal year 2025.
- C4 Therapeutics, Inc. showed an increase of +16.4% in Diluted EPS compared to the prior fiscal year.
- C4 Therapeutics, Inc. reported Total Assets of $359.07 million for fiscal year 2025.
- C4 Therapeutics, Inc. showed an increase of +2.7% in Total Assets compared to the prior fiscal year.
- C4 Therapeutics, Inc. reported Cash and Equivalents of $74.60 million for fiscal year 2025.
- C4 Therapeutics, Inc. showed an increase of +34.4% in Cash and Equivalents compared to the prior fiscal year.
- C4 Therapeutics, Inc. reported Long-Term Debt of $0.00 for fiscal year 2023.
- C4 Therapeutics, Inc. showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- C4 Therapeutics, Inc. reported Stockholders Equity of $256.59 million for fiscal year 2025.
- C4 Therapeutics, Inc. showed an increase of +18.8% in Stockholders Equity compared to the prior fiscal year.
- C4 Therapeutics, Inc. reported R&D Expense of $104.24 million for fiscal year 2025.
- C4 Therapeutics, Inc. showed a decrease of -5.8% in R&D Expense compared to the prior fiscal year.
- C4 Therapeutics, Inc. reported Operating Income of -$115.22 million for fiscal year 2025.
- C4 Therapeutics, Inc. showed an increase of +3.7% in Operating Income compared to the prior fiscal year.
- C4 Therapeutics, Inc. reported Shares Outstanding of 96.91 million shares for fiscal year 2025.
- C4 Therapeutics, Inc. showed an increase of +37.2% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: